Eli Lilly has entered a research collaboration and exclusive license agreement with Precision BioSciences to use genome editing to develop therapies for genetic disorders.
Intellia Therapeutics, Inc., a genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo.....
The two-year collaboration will employ Merck's CRISPR genome-editing technology in research studies by Dr. Jeffrey Gordon of Washington University School of Medicine.